Learning Objectives
| • EXPLAIN prevalence of obesity and adiposity-based chronic disease and the associated clinical risks |
| • DESCRIBE the care model for diagnosing, screening, and classifying obesity and ABCD |
| • REVIEW treatment options and goals for individuals with obesity and ABCD |
| • EXPLAIN prevalence of obesity and adiposity-based chronic disease and the associated clinical risks |
| • DESCRIBE the diagnosis, screening, and classifications of obesity and ABCD |
| • REVIEW treatment options and goals for individuals with obesity and ABCD |
Release Date:
Release Date: June 18, 2026
Expiration Date: June 18, 2029
Course Fee
FREE until 7/17/2026
There is no funding for this CPE activity.
ACPE UANs
Pharmacist: 0009-9999-26-015-H01-P
Pharmacy Technician: 0009-9999-26-015-H01-T
Session Codes
Pharmacist: 26UC15-HMJ87
Pharmacy Technician: 26UC15-MJH78
Accreditation Hours
0.05 CEU (0.5 Contact Hours)
Accreditation Statements
| The University of Connecticut School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit for the online activity ACPE UAN 0009-9999-26-015-H01-P/T will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program. |  |
Disclosure of Discussions of Off-label and Investigational Drug Use
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy and Pharmaceutical Sciences or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Faculty
Hazel Billings-Chiu, PharmD
PGY-2 Ambulatory Care Pharmacy Resident, UConn Health
Farmington, CT
Mariam A. Zedan, PharmD,
PGY-2 Ambulatory Care Pharmacy Resident, UConn Health
Farmington, CT
Jillian Carey, PharmD, BCACP
Pharmacy Clinical Coordinator, Primary Care
PGY2 Ambulatory Care Residency Program Director, UConn Health
Farmington, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy and Pharmaceutical Sciences requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Hazel Billings-Chiu, PharmD, Marian Zedan, PharmD, and Jillian Carey, PharmD have no financial relationships with ineligible companies.
CONTENT
Content
Pharmacist Post Test (for viewing only)
The ABCs of ABCD: Updates from the 2025 AACE Consensus Statement for the Evaluation and Treatment of Adults with Obesity and Adiposity-Based Chronic Disease
26-015 Pharmacist Post-Test
Pharmacist Learning Objectives:
1. EXPLAIN prevalence of obesity and adiposity-based chronic disease (ABCD) and the associated clinical risks
2. DESCRIBE the care model for diagnosing, screening, and classifying obesity and ABCD
3. REVIEW treatment options and goals for individuals with obesity and ABCD
*
1. Which of the following is considered an obesity-related disease?
a. Osteoarthritis
b. Type 2 Diabetes
c. Gastroesophageal reflux disease
*
2. According to CDC data, how many adults in the United States were classified as having obesity in 2024?
a. 1 out of 10 adults
b. 1 out of 5 adults
c. 1 out of 4 adults
*
3. What stage of ABCD would a 31-year-old female patient (height 62”, weight 93.2 kg, BMI 37.5 kg/m2) with no past medication history be considered to have?
a. Stage 0
b. Stage 1
c. Stage 2
*
4. Patient AH is a 64-year-old male (height 70”, weight 109 kg, BMI 34.4) with a history of type 2 diabetes. What is the minimum weight loss target that should be achieved for clinically meaningful benefit?
a. ≥ 10%
b. ≥ 12.5%
c. ≥ 15%
*
5. Which of the following is a contraindication to starting naltrexone/bupropion?
a. History of bulimia or anorexia nervosa
b. History of glaucoma
c. History of cholestasis
*
6. Which of the following is an evidence-based lifestyle recommendation to include in a treatment plan for a patient interested in losing weight?
a. Focus solely on aerobic exercise without resistance training
b. Adopt a reduced-calorie, nutrient dense eating pattern such as a Mediterranean-style diet
c. Prioritize intermittent fasting and sleep reduction to maximize energy expenditure
Pharmacy Technician Post Test (for viewing only)
The ABCs of ABCD: Updates from the 2025 AACE Consensus Statement for the Evaluation and Treatment of Adults with Obesity and Adiposity-Based Chronic Disease
26-015 Pharmacy Technician Post-Test
Pharmacy Technician Learning Objectives:
1. EXPLAIN prevalence of obesity and adiposity-based chronic disease (ABCD) and the associated clinical risks
2. DESCRIBE the diagnosing, screening, and classifying obesity and ABCD
3. REVIEW treatment options and goals for individuals with obesity and ABCD
*
1. Which of the following factors can impact obesity prevalence?
a. Technological advancements
b. Rates of routine laboratory screening
c. Healthcare access
*
2. According to CDC data, how many adults in the United States were classified as having obesity in 2024?
a. 1 out of 10 adults
b. 1 out of 5 adults
c. 1 out of 4 adults
*
3. Which of the following BMI’s would be classified as “Class I Obesity?”
a. 32 kg/m2
b. 37 kg/m2
c. 41 kg/m2
*
4. Which of the following weight loss medications is available as both an injection and an oral tablet?
a. Phentermine/Topiramate ER (Qsymia)
b. Semaglutide (Wegovy)
c. Liraglutide (Saxenda)
*
5. How much weight reduction is considered a “good” response to weight loss medication 3 months after initiation?
a. ≤ 5% weight reduction
b. >5% to <15% weight reduction
c. ≥ 15% weight reduction
*
6. Which of the following is an evidence-based lifestyle recommendation to include in a treatment plan for a patient interested in losing weight?
a. Focus solely on aerobic exercise without resistance training
b. Adopt a reduced-calorie, nutrient dense eating pattern such as a Mediterranean-style diet
c. Prioritize intermittent fasting and sleep reduction to maximize energy expenditure